JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boundy, V. A.
Right arrow Articles by Nestler, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boundy, V. A.
Right arrow Articles by Nestler, E. J.

Vol. 286, Issue 2, 1058-1065, August 1998

Regulation of cAMP-Dependent Protein Kinase Subunit Expression in CATH.a and SH-SY5Y Cells1

Virginia A. Boundy2, Jingshan Chen and Eric J. Nestler

Division of Molecular Psychiatry, Departments of Pharmacology and Psychiatry, Yale University School of Medicine, New Haven, Connecticut

Increasing evidence supports a role for adaptations in the cAMP pathway in mediating aspects of neural plasticity. These adaptations include altered levels of the catalytic (C) and regulatory (R) subunits of cAMP-dependent protein kinase (PKA) in specific neuronal cell types. In an effort to understand the mechanisms underlying this regulation of PKA, the effects of perturbing the cAMP pathway on PKA expression were examined in the locus ceruleus-like CATH.a cell line and the human neuroblastoma SH-SY5Y cell line. Exposure of CATH.a and SH-SY5Y cells to forskolin, a direct activator of adenylyl cyclase, resulted in a time-dependent decrease in levels of immunoreactivity of C and the two types of R (RI and RII). This decrease in PKA subunit immunoreactivity was not attenuated by pretreatment of the cells with the protein synthesis inhibitor cycloheximide. Moreover, exposure of the cell lines to forskolin had no effect on levels of mRNA for these PKA subunits over a wide time course. In contrast, treatment of cells with a cAMP antagonist (Rp-8-bromo-cAMPS) dramatically increased levels of PKA subunit immunoreactivity, particularly that of RI. No change in RI mRNA levels, however, was observed under these conditions. The PKA catalytic inhibitor H-89 did not attenuate the forskolin-induced down-regulation. The PKA subunit down-regulation was blocked, however, by treatment of the cells with Leu-Leu-Leu or lactacystin, inhibitors of proteasomes that are implicated in the regulated proteolysis of specific cellular proteins. Together, these findings demonstrate that regulation of PKA subunit expression by forskolin or a cAMP antagonist occurs primarily through post-transcriptional mechanisms and suggests the involvement of proteasome-mediated degradation in these phenomena.


0022-3565/98/2862-1058$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
L. S. Musil, A.-C. N. Le, J. K. VanSlyke, and L. M. Roberts
Regulation of Connexin Degradation as a Mechanism to Increase Gap Junction Assembly and Function
J. Biol. Chem., August 11, 2000; 275(33): 25207 - 25215.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.